US Capitol Capsule: Advance Science, Don't Pressure FDA On Approvals, Drug Chief Tells Advocates

"Patient advocacy groups should be in the business of advocating for patients, not advocating for specific drugs or development programs," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), insisted last week at the Biotechnology Industry Organization's 2015 Patient and Health Advocacy Summit in Washington.

"Patient advocacy groups should be in the business of advocating for patients, not advocating for specific drugs or development programs," Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research (CDER), insisted last week at the Biotechnology Industry Organization's 2015 Patient and Health Advocacy Summit in Washington.

"I don't think it's that healthy to engage patients and advocates for a drug," Woodcock told Scrip after the meeting....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Musculoskeletal

More from Therapeutic Category